Adient (ADNT) Q4 2026 Earnings Call Transcript

Adient reported fiscal 2026 revenue of $15.2 billion, up 4%, and adjusted EBITDA of $884 million, flat year over year, despite $41 million of Middle East conflict-related costs; adjusted EPS declined to $1.87 from $1.93. For fiscal 2027, management guided to revenue of $14.8 billion-$15.0 billion, adjusted EBITDA of $900 million-$925 million and free cash flow above $100 million, while citing roughly 1% lower global vehicle production, mix pressures and $30 million-$70 million in expected Canadian tariff headwinds. The board increased the share repurchase authorization by $400 million to approximately $1 billion of total flexibility, with about $100 million of buybacks planned for fiscal 2027 subject to conditions.

Analysis

The key issue is not whether Adient can hold margins in a weak production market; it is whether it can convert a large, largely unquantified recovery and productivity plan into EBITDA while revenue falls. Fiscal 2027 guidance implies improvement despite lower sales, persistent mix pressure, customer downtime and Canadian tariff costs management still has to recover. That makes execution—not the buyback authorization—the principal near-term valuation driver. A miss in customer recoveries or launch timing could expose the operating leverage of a supplier base facing OEM production cuts.

Cash quality also merits a discount: fiscal 2026 free cash flow benefited from timing items that reverse, while fiscal 2027 guidance is above $100 million and planned repurchases are about $100 million. The authorization is flexibility, not evidence of distributable cash beyond the plan. China adds a less visible risk: strength in consolidated operations and JV equity income may mask falling unconsolidated revenue as ICE volumes cede share and margin compression catches up. Conversely, the China domestic-OEM mix and the onshoring backlog are plausible medium-term offsets, but they do not eliminate the fiscal 2027 timing gap.

The likely operating trough is around the Americas model-change downtime in fiscal Q2, with management pointing to improvement toward late Q3/Q4; that recovery depends on OEM schedules and customer cost reimbursement. Over 6–18 months, automation, restructuring and the Nissan program may support economics, but the latter is not an immediate earnings catalyst. The contrarian risk to a bearish read is that production and launches outperform the conservative assumptions, while Adient achieves recoveries; evidence is not yet independently established.

Key Decisions for Investors

• Avoid chasing ADNT on the expanded repurchase authorization. Treat the planned buyback as conditional until quarterly free cash flow, net debt and actual repurchase pace confirm it is funded without weakening investment capacity.
• Keep ADNT neutral-to-underweight through the fiscal Q2 downtime window; reassess after results show customer recovery receipts, Americas margin performance and launch schedules. A recovery in late Q3/Q4 is a catalyst, not yet a base-case certainty.
• Use a failed-recovery trigger to revisit a short or hedge: customer reimbursement delays, further guidance reductions, or EBITDA tracking below the $900 million–$925 million range would undermine the operating-performance thesis. Falsification on the upside would be documented recoveries and margins improving despite lower sales.
• Monitor China separately from consolidated Asia: JV income, unconsolidated revenue and domestic-OEM program volumes will indicate whether mix diversification offsets ICE declines and deferred margin compression. Verify the FAA joint-venture sale's closing terms before assigning value to proceeds or cost benefits.